score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.E642K	0.2222	189.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf						0	0.0	0.0	0.0	EGFR p.E642K (Missense)	1.0	MEL-IPI_Pat16	MEL-IPI_Pat16-Tumor-SM-53U3E	MEL-IPI_Pat16-Normal-SM-53U5B
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.D792N	0.622	254.0	8e-06	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf						0	0.0	0.0	0.0	EGFR p.D792N (Missense)	1.0	MEL-IPI_Pat16	MEL-IPI_Pat16-Tumor-SM-53U3E	MEL-IPI_Pat16-Normal-SM-53U5B
Investigate Actionability	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability	Ipilimumab	CTLA-4 inhibition	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498													0				 mutations per Mb		MEL-IPI_Pat16		
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.E415K	0.1806	227.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14						0	5.0	0.0	0.0053	FLT3 p.E415K (Missense)	1.0	MEL-IPI_Pat16	MEL-IPI_Pat16-Tumor-SM-53U3E	MEL-IPI_Pat16-Normal-SM-53U5B
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.G578E	0.1489	235.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881													0	35.0	0.2857	0.7805	MET p.G578E (Missense)	0.0	MEL-IPI_Pat16	MEL-IPI_Pat16-Tumor-SM-53U3E	MEL-IPI_Pat16-Normal-SM-53U5B
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.E494K	0.2522	226.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf						0	121.0	0.3554	1.0	ABL1 p.E494K (Missense)		MEL-IPI_Pat16	MEL-IPI_Pat16-Tumor-SM-53U3E	MEL-IPI_Pat16-Normal-SM-53U5B
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.K212R	0.1975	238.0	0.0	0.0																Investigate Actionability	0.0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828	0	31.0	0.0	0.8783	BCOR p.K212R (Missense)		MEL-IPI_Pat16	MEL-IPI_Pat16-Tumor-SM-53U3E	MEL-IPI_Pat16-Normal-SM-53U5B
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat16		
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.D435E	0.3058	121.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0	0.0	0.0	0.0	BRCA1 p.D435E (Missense)	1.0	MEL-IPI_Pat16	MEL-IPI_Pat16-Tumor-SM-53U3E	MEL-IPI_Pat16-Normal-SM-53U5B
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.D435V	0.3109	119.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0	0.0	0.0	0.0	BRCA1 p.D435V (Missense)	1.0	MEL-IPI_Pat16	MEL-IPI_Pat16-Tumor-SM-53U3E	MEL-IPI_Pat16-Normal-SM-53U5B
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.S276F	0.3918	171.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf													0	43.0	0.4186	1.0	TET2 p.S276F (Missense)		MEL-IPI_Pat16	MEL-IPI_Pat16-Tumor-SM-53U3E	MEL-IPI_Pat16-Normal-SM-53U5B
Investigate Actionability			Guideline	Somatic Variant	PTPN11	Missense	p.N277I	0.2737	190.0	0.0	0.0																Investigate Actionability	0.0	Mutations in PTPN11 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	295.0	0.2983	1.0	PTPN11 p.N277I (Missense)		MEL-IPI_Pat16	MEL-IPI_Pat16-Tumor-SM-53U3E	MEL-IPI_Pat16-Normal-SM-53U5B
Biologically Relevant				Somatic Variant	SLC45A3	Missense	p.G136S	0.2055	73.0	0.0	0.0																					0	3.0	0.3333	0.0	SLC45A3 p.G136S (Missense)		MEL-IPI_Pat16	MEL-IPI_Pat16-Tumor-SM-53U3E	MEL-IPI_Pat16-Normal-SM-53U5B
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G1025E	0.2788	104.0	0.0	0.0																					0	0.0	0.0	0.0	ROS1 p.G1025E (Missense)		MEL-IPI_Pat16	MEL-IPI_Pat16-Tumor-SM-53U3E	MEL-IPI_Pat16-Normal-SM-53U5B
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P63L	0.7455	55.0	0.0	0.0																					0	0.0	0.0	0.0	CDKN2A p.P63L (Missense)		MEL-IPI_Pat16	MEL-IPI_Pat16-Tumor-SM-53U3E	MEL-IPI_Pat16-Normal-SM-53U5B
Biologically Relevant				Somatic Variant	COL1A1	Splice Site		0.3824	102.0	0.0	0.0																					0	2.0	0.0	0.0	COL1A1  (Splice Site)		MEL-IPI_Pat16	MEL-IPI_Pat16-Tumor-SM-53U3E	MEL-IPI_Pat16-Normal-SM-53U5B
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.F13L	0.2469	81.0	0.0	0.0																					0	23.0	0.2174	0.838	IL12RB1 p.F13L (Missense)		MEL-IPI_Pat16	MEL-IPI_Pat16-Tumor-SM-53U3E	MEL-IPI_Pat16-Normal-SM-53U5B
Biologically Relevant				Somatic Variant	TPX2	Missense	p.H335Y	0.3875	240.0	0.0	0.0																					0	34.0	0.5	0.9998	TPX2 p.H335Y (Missense)		MEL-IPI_Pat16	MEL-IPI_Pat16-Tumor-SM-53U3E	MEL-IPI_Pat16-Normal-SM-53U5B
Biologically Relevant				Copy Number	FLI1	Deletion				0.0	0.0																					0				FLI1 Deletion		MEL-IPI_Pat16	MEL-IPI_Pat16-Tumor-SM-53U3E	
Biologically Relevant				Copy Number	CHEK1	Deletion				0.0	0.0																					0				CHEK1 Deletion		MEL-IPI_Pat16	MEL-IPI_Pat16-Tumor-SM-53U3E	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion)		MEL-IPI_Pat16		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.791																									0				COSMIC Signature (version 2) 7 (79%)		MEL-IPI_Pat16		
